Iraklis Tsangaris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9285843/publications.pdf

Version: 2024-02-01

88 3,354 29 56
papers citations h-index g-index

88 88 88 4641
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3430-3436.	3.2	448
2	Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Critical Care Medicine, 2010, 38, 2229-2241.	0.9	240
3	Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Medicine, 2017, 15, 172.	5.5	132
4	Impact of catheter-related bloodstream infections on the mortality of critically ill patients: A meta-analysis*. Critical Care Medicine, 2009, 37, 2283-2289.	0.9	129
5	Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Intensive Care Medicine, 1998, 24, 296-303.	8.2	127
6	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. European Respiratory Journal, 2022, 60, 2102311.	6.7	124
7	Effect of the Prone Position on Patients with Hydrostatic Pulmonary Edema Compared with Patients with Acute Respiratory Distress Syndrome and Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 360-368.	5.6	119
8	Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clinical Microbiology and Infection, 2017, 23, 104-109.	6.0	105
9	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. Journal of Heart and Lung Transplantation, 2020, 39, 1435-1444.	0.6	104
10	Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Critical Care, 2012, 16, R149.	5.8	94
11	Bronchoalveolar lavage alterations during prolonged ventilation of patients without acute lung injury. European Respiratory Journal, 2003, 21, 495-501.	6.7	92
12	Metabolite Profiles in Sepsis: Developing Prognostic Tools Based on the Type of Infection*. Critical Care Medicine, 2016, 44, 1649-1662.	0.9	86
13	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically III Patients Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2013, 57, 668-671.	3.2	71
14	Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema American Journal of Respiratory and Critical Care Medicine, 1997, 155, 945-951.	5.6	66
15	The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. Critical Care, 2019, 23, 387.	5.8	63
16	Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Critical Care, 2013, 17, R247.	5.8	61
17	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. European Respiratory Journal, 2018, 52, 1800248.	6.7	61
18	Clinical review: Idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadne's thread. Critical Care, 2010, 14, 246.	5.8	60

#	Article	IF	CITATIONS
19	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. European Respiratory Journal, 2022, 59, 2102024.	6.7	57
20	Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infectious Diseases, 2009, 9, 213.	2.9	47
21	Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2014, 69, 1111-1118.	3.0	46
22	Procalcitonin as an early indicator of outcome in sepsis: a prospective observational study. Journal of Hospital Infection, 2011, 77, 58-63.	2.9	45
23	ASSOCIATION OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION WITH ELEVATED NT-pro-BNP IN GENERAL INTENSIVE CARE UNIT PATIENTS WITH PRESERVED EJECTION FRACTION. Shock, 2010, 33, 141-148.	2.1	44
24	Polymicrobial bloodstream infections: Epidemiology and impact on mortality. Journal of Global Antimicrobial Resistance, 2013, 1, 207-212.	2.2	43
25	Acute Severe Asthma. Drugs, 2009, 69, 2363-2391.	10.9	41
26	Improving outcomes of severe infections by multidrug-resistant pathogens with polyclonal IgM-enriched immunoglobulins. Clinical Microbiology and Infection, 2016, 22, 499-506.	6.0	38
27	PROGNOSTIC IMPORTANCE OF INCREASED PLASMA AMINO-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVELS IN A LARGE NONCARDIAC, GENERAL INTENSIVE CARE UNIT POPULATION. Shock, 2009, 31, 342-347.	2.1	36
28	The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clinical Chemistry and Laboratory Medicine, 2014, 52, 937-50.	2.3	35
29	Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Critical Care, 2009, 13, R172.	5.8	34
30	Increases in inflammatory and CD14dim/CD16pos/CD45pos patrolling monocytes in sepsis: correlation with final outcome. Critical Care, 2018, 22, 56.	5 . 8	32
31	The effect of exogenous surfactant in patients with lung contusions and acute lung injury. Intensive Care Medicine, 2007, 33, 851.	8.2	29
32	The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS. Thrombosis Research, 2009, 123, 832-836.	1.7	29
33	Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. Critical Care, 2017, 21, 48.	5 . 8	29
34	Steroids in Idiopathic Pulmonary Fibrosis Acute Exacerbation: Defenders or Killers?. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 587-588.	5.6	27
35	General Prognostic Scores in Outcome Prediction for Cancer Patients Admitted to the Intensive Care Unit. American Journal of Critical Care, 2011, 20, 56-66.	1.6	25
36	The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy. Medicine (United States), 2020, 99, e23365.	1.0	24

#	Article	IF	CITATIONS
37	Red blood cell transfusion affects microdialysis-assessed interstitial lactate/pyruvate ratio in critically ill patients with late sepsis. Intensive Care Medicine, 2012, 38, 1843-1850.	8.2	23
38	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	2.9	23
39	Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. Blood, 2012, 120, 1531-1532.	1.4	21
40	Pulmonary hypertension in patients with interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2018, 50, 38-46.	2.6	21
41	Epidemiology and initial management of pulmonary arterial hypertension: realâ€world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Pulmonary Circulation, 2019, 9, 1-12.	1.7	21
42	Late Peaks of HMGB1 and Sepsis Outcome: Evidence For Synergy With Chronic Inflammatory Disorders. Shock, 2019, 52, 334-339.	2.1	21
43	Pituitary-adrenal responses following major abdominal surgery. Hormones, 2008, 7, 237-242.	1.9	20
44	Kinetics of Adipose Tissue Microdialysis-Derived Metabolites in Critically III Septic Patients. Shock, 2011, 35, 343-348.	2.1	19
45	COVID-19 Infection-Related Coagulopathy and Viscoelastic Methods: A Paradigm for Their Clinical Utility in Critical Illness. Diagnostics, 2020, 10, 817.	2.6	19
46	Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation. Medicine (United States), 2016, 95, e3037.	1.0	18
47	Angiopoietin-2 Levels as Predictors of Outcome in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome. Disease Markers, 2017, 2017, 1-6.	1.3	18
48	Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension. Platelets, 2019, 30, 646-651.	2.3	18
49	TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infectious Diseases, 2011, 11, 309.	2.9	17
50	Gene Polymorphisms in the Heme Degradation Pathway and Outcome of Severe Human Sepsis. Shock, 2012, 38, 459-465.	2.1	17
51	Effect of angiotensin converting enzyme gene I/D polymorphism and its expression on clinical outcome in acute respiratory distress syndrome. Minerva Anestesiologica, 2013, 79, 861-70.	1.0	17
52	Use of IFN \hat{I}^3 /IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock. Frontiers in Immunology, 2021, 12, 607217.	4.8	15
53	The role of procalcitonin and IL-6 in discriminating between septic and non-septic causes of ALI/ARDS: a prospective observational study. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1535-42.	2.3	14
54	Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial. Critical Care, 2022, 26, .	5.8	14

#	Article	IF	CITATIONS
55	Individualized significance of the â^251 A/T single nucleotide polymorphism of interleukin-8 in severe infections. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 563-570.	2.9	13
56	Coagulation Profiles of Pulmonary Arterial Hypertension Patients, Assessed by Non-Conventional Hemostatic Tests and Markers of Platelet Activation and Endothelial Dysfunction. Diagnostics, 2020, 10, 758.	2.6	13
57	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	2.9	13
58	The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. Blood Coagulation and Fibrinolysis, 2010, 21, 175-181.	1.0	10
59	The evolving role of the renin–angiotensin system in ARDS. Critical Care, 2017, 21, 329.	5.8	9
60	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. Journal of Heart and Lung Transplantation, 2022, 41, 971-981.	0.6	9
61	Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?. European Respiratory Journal, 2012, 40, 794-795.	6.7	8
62	Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis. BMC Immunology, 2014, 15, 585.	2.2	8
63	Improving Patient Care in Pulmonary Arterial Hypertension: Addressing Psychosocial Issues. Journal of Clinical Hypertension, 2014, 16, 159-161.	2.0	8
64	The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension. Diagnostics, 2021, 11, 1200.	2.6	8
65	Epidemiology and Management of Chronic Thromboembolic Pulmonary Hypertension in Greece. Real-World Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Journal of Clinical Medicine, 2021, 10, 4547.	2.4	8
66	Cardiac Catheterization versus Echocardiography for Monitoring Pulmonary Pressure: A Prospective Study in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Diagnostics, 2020, 10, 49.	2.6	7
67	Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE). Hellenic Journal of Cardiology, 2022, 64, 93-96.	1.0	7
68	Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension. Diagnostics, 2022, 12, 1238.	2.6	7
69	Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism and circulating ACE levels are not associated with outcome in critically ill septic patients. Clinical Chemistry and Laboratory Medicine, 2012, 50, 293-9.	2.3	6
70	Clinical Usefulness of Novel Serum and Imaging Biomarkers in Risk Stratification of Patients with Stable Angina. Disease Markers, 2014, 2014, 1-14.	1.3	6
71	The Effect of Plasma Homocysteine Levels on Clinical Outcomes of Patients With Acute Lung Injury/Acute Respiratory Distress Syndrome. American Journal of the Medical Sciences, 2009, 338, 474-477.	1.1	5
72	Preclinical Pulmonary Capillary Endothelial Dysfunction is Present in Brain Dead Subjects. Pulmonary Circulation, 2013, 3, 419-425.	1.7	5

#	Article	IF	CITATIONS
73	Pulmonary Hypertension in Parenchymal Lung Disease. Pulmonary Medicine, 2012, 2012, 1-14.	1.9	4
74	Survival after multiple traumas is associated with improved outcomes from gram-negative sepsis: Clinical and experimental evidence. Journal of Infection, 2017, 74, 163-171.	3.3	4
75	The impact of cardiovascular comorbidities associated with risk for left heart disease on idiopathic pulmonary arterial hypertension: Data from the Hellenic Pulmonary Hypertension Registry (HOPE). Pulmonary Circulation, 2022, 12, .	1.7	4
76	Pulmonary hypertension and lung diseases: a suggestion for revision of the clinical classification. European Respiratory Journal, 2010, 35, 700-701.	6.7	3
77	Life-threatening antineutrophil cytoplasmic antibody–associated vasculitis after influenza A H1N1 infection requiring veno-venous extracorporeal membrane oxygenation. Perfusion (United Kingdom), 2020, 35, 546-549.	1.0	3
78	Postobstructive Pulmonary Edema. Chest, 2007, 132, 2056.	0.8	2
79	Ovarian hyperstimulation syndrome complicated by severe communityâ€acquired pneumonia due to methicillinâ€resistant Staphylococcus aureus positive for Pantonâ€Valentine leukocidin. Journal of Obstetrics and Gynaecology Research, 2012, 38, 476-478.	1.3	2
80	Cardiovascular risk in pulmonary alveolar proteinosis. Expert Review of Respiratory Medicine, 2016, 10, 235-240.	2.5	2
81	Life-threatening aortic thrombosis in a trauma patient homozygous for factor V Leiden mutation: Case report. Thrombosis Journal, 2011, 9, 8.	2.1	1
82	Do Not Forget Pulmonary Hypertension in Asplenic Patients. American Journal of Medicine, 2008, 121, e21.	1.5	0
83	Inhaled vasodilators for pulmonary hypertension in left heart disease: Should we start considering?*. Critical Care Medicine, 2009, 37, 1155-1156.	0.9	0
84	A PATIENT WITH INFLUENZA A INFECTION AND ANCA-ASSOCIATED VASCULITIS. Chest, 2019, 156, A223.	0.8	0
85	Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment., 2017,,.		0
86	Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. , 2017, , .		0
87	Survival in medically treated chronic thromboembolic pulmonary hypertension patients., 2018,,.		0
88	Soluble fms-like tyrosine kinase 1, placental growth factor and procalcitonin as biomarkers of gram-negative sepsis. Medicine (United States), 2021, 100, e27662.	1.0	0